Alice Zhang was a graduate student in neuroscience when she realized that the drug discovery process could be revolutionized by rapid advances in multiple fields. Then she decided that she’d be the one to revolutionize it. Today, she leads Verge Genomics, which aims to develop better drugs faster using artificial intelligence and an “all-in-human” approach.
Our weekly newsletter with insights and intelligence from across the firm
By submitting this information, you agree to receive marketing emails from Goldman Sachs and accept our privacy policy. You can opt-out at any time.